Unique ID issued by UMIN | UMIN000010589 |
---|---|
Receipt number | R000012330 |
Scientific Title | A phase II study of TEGAFOX as adjuvant therapy for elderly patients with stage III and stage II colorectal cancer with risk factors for recurrence. |
Date of disclosure of the study information | 2013/04/30 |
Last modified on | 2019/10/29 09:18:59 |
A phase II study of TEGAFOX as adjuvant therapy for elderly patients with stage III and stage II colorectal cancer with risk factors for recurrence.
A phase II study of TEGAFOX as adjuvant therapy for with stage III and stage II colorectal cancer with risk factors for recurrence.
A phase II study of TEGAFOX as adjuvant therapy for elderly patients with stage III and stage II colorectal cancer with risk factors for recurrence.
A phase II study of TEGAFOX as adjuvant therapy for with stage III and stage II colorectal cancer with risk factors for recurrence.
Japan |
colon cancer
Gastrointestinal surgery |
Malignancy
NO
To evaluate the feasibility of the TEGAFOX followed by UFT/LV for patients with stage III and stage II colon cancer with risk factors of recurrence.
Safety,Efficacy
feasibility
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
UFT 300mg per m2 per day and LV 75mg per day for 28 days
Oxaliplatin:85mg/m2 day1,15
every 5-weeks for 3-cycle
After this therapy, followed by UFT/LV
2-cycle
70 | years-old | <= |
Not applicable |
Male and Female
1)with histologically confirmed colorectal cancer
2)with histologically confirmed stageIII and stageII colorectal cancer stageII:has at least one of the following factors
-ileus
-vascular invasion-positive
-T4
-poorly differentiated adenocarcinoma or undifferentiated carcinoma
-perforaiton
-lymph node dissection:less than 12
3)>=D2 lymph node dissection
4)Pathological curability is A or B
5)is aged 70 and over
6)Performance status 0-1
7)Without prior anti-tumor therapy
8)Adequate organ function
9)can start the therapy within 8weeks after surgery.
10)can take drugs orally.
11)whose written consent is taken.
1)Multiple malignancies within five
years
2) Other severe complications, such as
pulmonary emphysema, pulmonary fibrosis, hyper pulmonary
emphysema,paralysis intestinal,
intestinal obstruction, uncontrollable diabetes, cirrhosis, uncontrollable
hypertension, myocardial infarction
within six months, angina.
3)has severe diarrhea
4)with psychosis or psychoneyrosis
5) In case that the doctor judged that he/she is disqualified for the enrollment in this clinical trial.
75
1st name | |
Middle name | |
Last name | Kimihiko Funahashi |
Toho University Medical Center Omori hospital
Depaetment of Gastoroenterological Surgery
6-11-1, Omori-nishi Ota-ku, Tokyo, Japan
03-3762-4151
kingkong@med.toho-u.ac.jp
1st name | |
Middle name | |
Last name | Kimihiko Funahashi |
Toho University Medical Center Omori hospital
Depaetment of Gastoroenterological Surgery
6-11-1, Omori-nishi Ota-ku, Tokyo, Japan
03-3762-4151
kingkong@med.toho-u.ac.jp
Toho University Medical Center Omori hospital
Toho University Medical Center Omori hospital
Self funding
NO
2013 | Year | 04 | Month | 30 | Day |
Unpublished
Terminated
2013 | Year | 02 | Month | 13 | Day |
2015 | Year | 06 | Month | 03 | Day |
2013 | Year | 04 | Month | 12 | Day |
2021 | Year | 03 | Month | 31 | Day |
2013 | Year | 04 | Month | 24 | Day |
2019 | Year | 10 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012330
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |